Peptides studied in incretin, amylin, and energy-metabolism research models.
Research Articles
What Is 5-Amino-1MQ Studied For? Plain Guide | Artemis Labs
5-Amino-1MQ is a small molecule, not a peptide. What NNMT does, what blocking it means, and why the published record is entirely rodent and…
Read article →Article5-Amino-1MQ Salt Forms: Chloride vs Iodide | Artemis Labs
The chloride is CID 176507677 at 194.66 with no registered CAS. The iodide is CAS 42464-96-0 at 286.11. Mixing them creates a 1.47x molarity…
Read article →Article5-Amino-1MQ Muscle and Metabolism Research | Artemis Labs
What the aged-mouse muscle studies actually measured, why the ~70% figure is a recovery-after-injury result in aged male mice, and the counter-evidence usually left…
Read article →Article5-Amino-1MQ Human Evidence: There Is None | Artemis Labs
Zero human studies exist for 5-Amino-1MQ or any NNMT inhibitor. How that zero was verified across seven PubMed searches and a registry query, and…
Read article →ArticleRetatrutide Verification Checklist 2026
10-point research-grade retatrutide verification checklist — third-party HPLC, MS identity, COA review, and red-flag detection after the 2025–2026 quality crisis.
Read article →ArticleGLP-1 Receptor Agonism Explained: Molecular Mechanism Deep Dive
Deep dive on GLP-1 receptor agonism — binding affinities, signaling cascades, GIP/GLP-1 dual agonism, and triple-agonist research from 2024–2026 literature.
Read article →ArticleRetatrutide Quality Crisis: 37 Samples Failed Testing
Independent re-testing documented ~47% retatrutide failure rates across the 2025–2026 market. How to verify your batch and what real third-party testing requires.
Read article →ArticleTirzepatide vs Retatrutide: Mechanism & Efficacy 2026
Side-by-side comparison of tirzepatide (GLP-1/GIP dual) and retatrutide (GLP-1/GIP/glucagon triple) — efficacy, mechanism, safety, and research selection criteria.
Read article →ArticleTRIUMPH-4 Retatrutide Trial Design 2026
TRIUMPH-4 retatrutide Phase 3 trial design — Phase 3 outcomes pending; Phase 2 data (PMID 37366315) shows up to 24.2% mean weight reduction at…
Read article →ArticleSLU-PP-332: Exercise-Mimetic ERRα Agonist 2026
SLU-PP-332 ERRα agonist deep dive — mechanism, the 2023 Saint Louis University publication, exercise-mimetic transcriptional signature, and 2024-2026 follow-up research.
Read article →Related Products
Mitochondrial & NAD+ Research
Metabolic Research
Metabolic Research